GP Railway Workshops Heart Week Event Dr Chris Judkins MBBS MClinRes FRACP Interventional Cardiologist WA Cardiology Fiona Stanley.

Slides:



Advertisements
Similar presentations
Bioresorbeerbare “stents”
Advertisements

Stroke Mark Sudlow Consultant and Senior Lecturer
IRTB - Arterial Access and Angioplasty Dr Hilary White Nottingham.
Arteriosclerosis By: Timothy Granter & Megan Heath.
Ischaemic Heart Disease for the GP Chris Tracey GPVTS.
Managing Diabetes Medications. Topics What medications are available to –Manage diabetes? –Lower blood pressure? –Improve cholesterol? How can you keep.
Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.
Coronary Artery Disease. What is coronary artery disease? A narrowing of the coronary arteries that prevents adequate blood supply to the heart muscle.
Coronary Artery Disease: Diagnosis and Treatment
Risks & Prevention for Young Adults Cardiovascular Disease Kristen Hinners.
By Dr. Zahoor 1. ISCHAEMIC HEART DISEASE (IHD) Why myocardial ischaemia occurs?  Myocardial Ischaemia occurs when there is less supply of oxygen to the.
Angina and MI.
Stenting: Function, Problems, and Procedure. Uses for Stents  Peripheral artery disease (PAD)  Renal vascular hypertension  Hemodialysis access maintenance.
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
Management of Stable Angina SIGN 96
Pharmacotherapy after myocardial infarction The reality of coronary prevention in Brno, or else Is pharmacotherapy after myocardial infaction sufficient.
Atherosclerosis by Sidrah naseem (ug-3). Arteries are blood vessels that carry oxygen and nutrients from your heart to the rest of your body. Healthy.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
DR. ZAHOOR 1.  A 50 year old man presents to clinic with a complaint of central chest discomfort of 2 weeks’ duration, occurring after walking for more.
Secondary Prevention & Cardiac Rehabilitation Malcolm Walker Consultant Cardiologist UCLH & the Heart Hospital, London.
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Group work 5 Hypertension case discussions. Objectives At the end of this session, the trainees should: Be able to explain steps of correct BP measurement.
Rehabilitating Your Heart A Presentation of the Department of Cardiology of the Mount Pleasant Regional Hospital.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Non-communicable Disease Coronary Heart Disease
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Diagnosis, Management, & Follow-up Care Of CAD/AMI BARRY BERTOLET, MD CARDIOLOGY ASSOCIATES OF NORTH MS.
Antiplatelets, Anticoagulants What are the consequences Dr Jeremy Wright Cardiologist Hearts1st, Greenslopes Private Hospital.
 This disease Narrows the blood vessels that carry oxygen-rich blood to your heart. This happens because of plaque build up in the vessels.  The coronary.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Lecture v Coronary Artery Disease Dr. Aya M. Serry 2015/2016.
Dissolvable Heart Stents Richard Melpignano. Coronary Heart Disease Coronary Heart Disease (CHD) is, as of 2012, the leading cause of death worldwide.
Dr. Sohail Bashir Sulehria
 Ischaemic heart disease reduces blood supply to the heart muscles and is one of the major cardiovascular diseases.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Anesthetic management of patients with coronary stents Dr. S. Parthasarathy MD, DA, DNB, Dip Diab.MD,DCA, Dip software based statistics, PhD (physiology)
Laboratory Testing For Cardiovascular Risk
Cardiac update for GPs - Chest pain/angina Sanjay Sastry Consultant Cardiologist Royal Bolton Hospital Royal Bolton Hospital Manchester Heart Centre Wigan.
Management Strategies for Post-Intervention in Patients with CAD VBWG.
The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.
The OPTImal CArdiac REhabilitation (OPTICARE) trial:
Heart Attack By: Taylor.
CHU TIMONE, Marseille, FR
The Society for Cardiovascular Angiography & Interventions (SCAI) Foundation Charles E. Chambers, MD, FSCAI President Elect, Society for Cardiovascular.
Latvian Centre of Cardiology real-life registry
Baseline characteristics and effectiveness results
Heart Attack.
CASE HISTORY ISCHEMIC HEART DISEASE
Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.
what is carotid angioplasty?
Life after a Cardiovascular Event
Ischaemic Heart Disease Acute Coronary Syndrome
The Anglo Scandinavian Cardiac Outcomes Trial
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
Single Stage CABG and Peripheral Arterial Bypass for Combined Coronary and Peripheral Arterial Disease Divya Arora, Ashok Chahal and Shamsher Singh Lohchab.
Emily Bainbridge & Olivia Palmer 3/23/2018 Period B
Glenn N. Levine et al. JACC 2016;68:
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Preventive Angioplasty in Myocardial Infarction Trial
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
Train-the-Trainer Cases
Heart Disease Dr Stasinos Theodorou
Train-the-Trainer Cases
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Train-the-Trainer Cases
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

GP Railway Workshops Heart Week Event Dr Chris Judkins MBBS MClinRes FRACP Interventional Cardiologist WA Cardiology Fiona Stanley Hospital

 What is Coronary Intervention ?  What are the latest developments?  Aftercare post Stenting

 What is it?  How does it work?  What happens after stenting?

 Angiography  Mason Sones accidentally catheterised the LM – cardiac arrest  POBA  Sept , Switzerland, Andreas Gruentzig  Limited by dissections, recoil, acute closure (5%), restenosis  BMS  Introduced 1986 – Palmaz Schatz – approved FDA 1994  Better than POBA (Stress and Benestent-1 trials)  Neointimal hyperplasia 20-30%  DES  Introduced to overcome NIH  Issue of late thrombosis (drug prevents endothelialisation)  DEB  2 available – Useful where a stent is not desirable, ISR etc  Bioabsorbable scaffolds  Polymer of L-lactic acid (PLLA) (others magnesium etc)  Abbott Vascular – ”Absorb” TGA 2014

 Patients prefer Radial (wrist) Access  Back pain  BMI  Unable to lie flat  Less bleeding  Less Mortality  Same day stenting

Access site Bleeding Complications Major and Minor CaseComplicationTreatment Required FEMORAL 1 Pseudoaneurysm and retroperitoneal bleed US compression + transfusion 2 units 2 Haematoma >5cm - Transfusion Prolonged digital comp (3hr) and transfusion 2units 3 Haematoma >5cm - No transfusion Digital compression 90mins 4 Haematoma >5cm - No transfusion Digital compression 40mins 5 Retroperitoneal bleed Wait and watch 6-20Haematoma <5cm Digital compression <30mins RADIAL 21Haematoma <2cm2 nd TR band

 Lifestyle:  Diet  Exercise  Risk Factors:  Diabetes  Hypertension  Cholesterol  Smoking Other Considerations: Work/Driving Medications Comorbidities Obstructive sleep apnea

 Arterial access site  Driving  Diet  Exercise  Work Personal vehicleCommercial vehicle after a heart attack2 weeks4 weeks After a stent2 days4 weeks After bypass grafts4 weeks3 months

Medications 1. Aspirin 2. Clopidogrel (Plavix), Ticagrelor (Brilinta) 3. Statin (eg Atorvastatin) 4. Beta Blocker (eg Metoprolol) 5. ACE Inhibitor (eg ramipril)  Drug eluting stent (DES):12 months  Bare Metal Stent (BMS):3 months  After a heart attack:12 months  Bioresorbable stent:?12 months

Medications 1. Aspirin 2. Clopidogrel (Plavix), Ticagrelor (Brilinta) 3. Statin (eg Atorvastatin) 4. Beta Blocker (eg Metoprolol) 5. ACE Inhibitor (eg ramipril)  Drug eluting stent (DES):12 months  Bare Metal Stent (BMS):3 months  After a heart attack:12 months  Bioresorbable stent:?12 months

Secnario One: 65yo male Not diabetic Normal high blood pressure Smoker Borderline high cholesterol Scenario Two: Lower SBP by 10mmHg Lower cholesterol to target Quit smoking Absolute Risk 28% down to 8%

 Tertiary Hospitals Rehabilitation programs  HeartBeat (Armadale/Kelmscott)   Heart Foundation  My Heart My Life App/Book  Cardiovascular care WA (aka CPRwa)  Hollywood hospital   Perth Heart 